Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease

Investigators had previously shown, first in autopsies and then with biopsies, that the submandibular gland, the saliva-producing gland in the neck, has the signature alpha-synuclein microscopic pathology of Parkinson's disease and that the gland can be biopsied to provide an unambiguous confirmation of diagnosis. "This new work shows, in autopsies, that the submandibular gland also has the same signature alpha-synuclein pathology in a high proportion of subjects diagnosed during life with dementia with Lewy bodies. Biopsy of the submandibular gland then also may be able to provide a more accurate diagnosis of dementia with Lewy bodies during life," explained lead investigator Thomas G. Beach, MD, PhD, Head and Senior Scientist at the Civin Laboratory for Neuropathology, Director of the Brain and Body Donation Program, Banner Sun Health Research Institute (BSHRI), Phoenix, Arizona.

Lewy-type α-synucleinopathy (LTS) is found in the brains of all Parkinson's disease patients when they are autopsied. For a number of other diseases related to Lewy bodies, this same pathology is present. This study involved subjects with central-nervous-system Lewy-type diseases and a control group without Lewy-type pathology. Both groups were composed of elderly subjects who had volunteered for the Arizona Study of Aging and Neurodegenerative Disorders and the Brain and Body Donation Program (BBDP).

When LTS is present, it is possible to see it by using an immunohistochemical staining technique. In the image, the dark line is a nerve fiber in the submandibular gland, made visible with the stain. This finding was not observed in normal control subjects.

In this study, submandibular gland alpha-synuclein pathology was found in 42/47 (89%) of autopsies of individuals with Parkinson's disease and 20/28 (71%) of those with dementia with Lewy bodies, but in none of the 110 control subjects.

The subjects had a variety of conditions. Those with Lewy body disorders included 46 with Parkinson's disease, 28 with dementia with Lewy bodies (DLB), nine with incidental Lewy-body disease, 33 with Alzheimer's disease with Lewy bodies, and two with progressive supranuclear palsy with Lewy bodies (PSPLB). Control subjects, defined as individuals without central-nervous-system LTS, included 79 normal elderly subjects, 15 with Alzheimer's disease, 12 with progressive supranuclear palsy, two with corticobasal degeneration and two with multiple system atrophy (MSA).

In the specific case of DLB, Dr. Beach emphasized that this study is important because, "The low diagnostic accuracy, during life, for dementia with Lewy bodies, has made it difficult to conduct effective clinical trials of possibly helpful new drugs. With better diagnostic accuracy, clinical trials would have a higher chance of success and could be done more quickly and at lesser cost. The next step will be to do biopsies of the submandibular gland in living people with dementia with Lewy bodies to confirm these autopsy results."